Overall, animal studies indicated that the combination of paProtacL‐Survivin and paCas9‐Survivin had the most robust ability to reduce Survivin protein and to inhibit tumour growth than either paProtacL‐Survivin or paCas9‐Survivin alone. This evidence concerns the gene BIRC5 and neoplasm.